本帖最后由 老马 于 2013-3-13 13:43 编辑 4 W& l& L- |+ @) d
2 \4 p5 i( [6 g健择(吉西他滨)+顺铂+阿瓦斯汀
7 o! l. F; d- N R; q6 Z Gemzar +Cisplatin + Avastin
/ Y; u) r3 d0 M a& Ahttp://annonc.oxfordjournals.org/content/21/9/1804.full! F: u! t2 p$ H! O2 q
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) + \- u: z% J' S7 P6 ^8 ?
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. ! I7 W, G3 i j. Q8 j/ ?# w
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
5 w" S" r; \0 G
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 840)
0 q4 a8 I# s q4 z" p! w9 m3 {华为网盘附件:
1 D7 I: b. M, x【华为网盘】ava.JPG
' @, n( \! `+ L6 T& M' P4 o |